Try a new search

Format these results:

Searched for:

in-biosketch:true

person:katzs04

Total Results:

151


My treatment approach to the management of ulcerative colitis

Katz, Seymour
Ulcerative colitis diagnosis and management represent a challenge for clinicians. The disguises of ischemia and acute infectious colitis continue to confound the diagnosis. The therapeutic options have remarkably expanded in the way of immunomodulators, biologics, or ileoanal pouch surgery, yet all carry potential considerable risks. These risks can confuse and impair patient acceptance, particularly elderly patients and men younger than 30 years. Predictors of outcome of medical and surgical therapy have improved but are far from complete. Nevertheless, therapies focused on the specific patient's condition continue to offer hope.
PMID: 23910410
ISSN: 0025-6196
CID: 484132

Retained capsule extraction 6years after wireless bowel capsule endoscopy: The importance of follow up [Letter]

Lipka, Seth; Vacchio, Anthony; Katz, Seymour; Ginzburg, Lev
PMID: 23332558
ISSN: 1873-9946
CID: 394772

Reversible pseudoachalasia in a patient with laparoscopic adjustable gastric banding

Lipka, Seth; Katz, Seymour
PMCID:3736786
PMID: 23935558
ISSN: 1554-7914
CID: 1446182

Massive pyoderma gangrenosum in a 77 year old female with Crohn's disease responsive to adalimumab [Letter]

Lipka, Seth; Katz, Seymour; Ginzburg, Lev
PMID: 22926276
ISSN: 1873-9946
CID: 988622

Elderly-onset IBD: a milder disease?

Ha, Christina; Katz, Seymour
Patients with elderly-onset IBD are more likely to have marked comorbidities and polypharmacy than those diagnosed at a younger age, which might affect therapeutic decision-making. Increased knowledge of this higher-risk group might guide patient management. Data from a large population-based study evaluating the clinical presentation and course of elderly-onset IBD are discussed.
PMID: 23545521
ISSN: 1759-5045
CID: 386642

Factors Influencing the Treatment of Inflammatory Bowel Disease in Patients With Cancer Recurrence: Pilot Study [Meeting Abstract]

Bahamonde, Lourdes G; Velayos, Fernando S; Katz, Seymour; Lipka, Seth; Shapira, Iuliana; Sultan, Keith
ISI:000322997202274
ISSN: 0016-5085
CID: 1446312

"One more time" 5-ASA retrial after a glucocorticosteroid induced remission in moderate to severe ulcerative colitis: a prospective community practice experience [Letter]

Lipka, Seth; Katz, Seymour; Kaur, Navroop
PMID: 22871515
ISSN: 1873-9946
CID: 1446192

Prevention, detection, and treatment of osteopenia and osteoporosis

Katz, Seymour
PMCID:3745207
PMID: 23961268
ISSN: 1554-7914
CID: 503632

Factors Influencing the Treatment of Inflammatory Bowel Disease in Patients with Cancer Recurrence: Pilot Study [Meeting Abstract]

Bahamonde, Lourdes; Lipka, Seth; Rosen, Lisa; Sultan, Keith; Velayos, Fernando; Shapira, Iuliana; Katz, Seymour
ISI:000208839702595
ISSN: 1572-0241
CID: 1446262

Prognosis of lymphoma in patients following treatment with 6-mercaptopurine/azathioprine for inflammatory bowel disease

Sultan, Keith; Korelitz, Burton I; Present, Daniel; Katz, Seymour; Sunday, Suzanne; Shapira, Iuliana
BACKGROUND: 6-Mercaptopurine (6-MP) and azathioprine (AZA) are effective for induction and maintenance therapy of Crohn's disease (CD) and ulcerative colitis (UC). There is an increased risk of lymphoma in patients with inflammatory bowel disease (IBD) treated with 6-MP/AZA. Little, however, is known about the prognosis of IBD patients treated with 6-MP/AZA who develop lymphoma. METHODS: We conducted a retrospective review of 8780 records from three tertiary IBD centers and the records of 600 lymphoma patients from an academic Hematology and Oncology Center. The primary endpoint variable was survival of IBD patients with a lymphoma diagnosis treated or not treated with 6-MP/AZA. A secondary endpoint was the relative survival rate (by gender, race, and ethnicity) extrapolated from the Surveillance Epidemiology and End Results (SEER) database, computed for each subject. RESULTS: Fourteen IBD patients were diagnosed with lymphoma. Twelve had CD and two had UC. Seven patients had treatment with 6-MP/AZA and seven had not. Two patients who received 6-MP/AZA died (both 1 year after diagnosis) and two patients who had not received 6-MP/AZA died (one after 2 years, another 3 years after diagnosis), all from lymphoma. Survival at last follow-up was similar to expected survival based on extrapolated SEER data for both 6-MP/AZA treated and untreated patients. CONCLUSIONS: We found no differences of survival with lymphoma between IBD patients and expected survival for the general population. Also, the prognosis for those IBD patients treated with 6-MP/AZA was not worse than lymphoma patients not treated with 6-MP/AZA. Statistical analysis, however, was limited by the small sample size and heterogeneity of the patients studied.
PMID: 22241664
ISSN: 1078-0998
CID: 491712